HPLC-DAD protein kinase inhibitor analysis in human serum.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

• Publication date

  2012-04-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.jchromb.2012.02.037PMID 22425385
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma.

  2011cited by this paper
• Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.

  2011cited by this paper
• Imatinib Quantification in Human Serum for Clinical Purposes using High-performance Liquid Chromatography with a Diode Array Detector.

  2011cited by this paper
• A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.

  2010cited by this paper
• Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.

  2010cited by this paper
• Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry.

  2010cited by this paper
• Phase I Trial of Pazopanib in Patients with Advanced Cancer

  2009cited by this paper
• A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

  2009cited by this paper
• The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry.

  2007cited by this paper
• Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.

  2006cited by this paper
• Metabolism and Disposition of Vatalanib (PTK787/ZK-222584) in Cancer Patients

  2006cited by this paper
• Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection.

  2005cited by this paper
• Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule

  2004cited by this paper
• Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor.

  2003cited by this paper
• Measurement of total mirtazapine and normirtazapine in plasma/serum by liquid chromatography with fluorescence detection.

  2003cited by this paper
• Separation methods for antiviral phosphorus-containing drugs.

  2001cited by this paper
• Determination of phosphonoformate (foscarnet) in calf and human serum by automated solid-phase extraction and high-performance liquid chromatography with amperometric detection.

  1999cited by this paper
• Kombination von DC, GC (OV1 und OV17) und HPLC (RP18) zur schnellen Erkennung von Arzneimitteln, Rauschmitteln und verwandten Verbindungen

  1981cited by this paper

• Identification and assessment of novel degradants in pazopanib hydrochloride using stability-indicating RP-HPLC method

  2025cites this paper
• A validated and environmentally sustainable high-performance thin-layer chromatography method for the concurrent analysis of axitinib, pazopanib, crizotinib, ruxolitinib, and ibrutinib in bulk drug substances and pharmaceutical formulations

  2025cites this paper
• Determination of Tyrosine Kinase Inhibitors as Antineoplastic Agents in Pharmaceutical and Biological Matrices: An Overview of Recent Analytical Techniques

  2025cites this paper
• Development of a molecularly imprinted electrochemical sensor for erlotinib detection using a modified screen-printed carbon electrode

  2025cites this paper
• Therapeutic Drug Monitoring of Pazopanib in Renal Cell Carcinoma and Soft Tissue Sarcoma: A Systematic Review

  2024cites this paper
• Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma

  2023cites this paper
• Optimization of Chromatographic Conditions with QbD for Method Development and Validation of Bosutinib by HPLC: Applications in Dosage Forms and Rat Plasma Analysis

  2023cites this paper
• Comparison of a newly developed high performance liquid chromatography method with diode array detection to a liquid chromatography tandem mass spectrometry method for the quantification of cabozantinib, dabrafenib, nilotinib and osimertinib in human serum - Application to therapeutic drug monitorin

  2022cites this paper
• Digital Twins for Continuous Biologics Manufacturing

  2021cites this paper
• Towards Autonomous Operation by Advanced Process Control—Process Analytical Technology for Continuous Biologics Antibody Manufacturing

  2021cites this paper
• Simultaneous determination of nine tyrosine kinase inhibitors in three complex biological matrices by using high performance liquid chromatography-diode array detection combined with a second-order calibration method.

  2021cites this paper
• Comparison of three chemometric methods for processing HPLC-DAD data with time shifts: Simultaneous determination of ten molecular targeted anti-tumor drugs in different biological samples.

  2020cites this paper
• Possibility for dose optimization of pazopanib from its plasma concentration in Japanese patients with cancer.

  2020cites this paper
• Nuevas metodologías analíticas para el control de compuestos quimioterápicos en matrices biológicas

  2019cites this paper
• The redox mechanism investigation of non-small cell lung cancer drug: Erlotinib via theoretical and experimental techniques and its host–guest detection by β-Cyclodextrin nanoparticles modified glassy carbon electrode

  2019cites this paper
• Simultaneous determination of temperature and erlotinib by novel carbon-based sensitive nanoparticles

  2018cites this paper
• Simultaneous monitoring of pazopanib and its metabolites by UPLC–MS/MS

  2018cites this paper
• Imatinib quantification in human serum with LC-MS3 as an effective way of protein kinase inhibitor analysis in biological matrices

  2017cites this paper
• Determination of dasatinib in the tablet dosage form by ultra high performance liquid chromatography, capillary zone electrophoresis, and sequential injection analysis.

  2017cites this paper
• Antineoplastic drugs and their analysis: a state of the art review.

  2017cites this paper
• Simultaneous Determination of Erlotinib and its Metabolites in Human Urine and Serum Samples by High-Performance Liquid Chromatography

  2017cites this paper
• Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology.

  2016cites this paper
• Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS.

  2016cites this paper
• Simultaneous determination of erlotinib and tamoxifen in rat plasma using UPLC-MS/MS: Application to pharmacokinetic interaction studies.

  2016cites this paper
• Bioequivalence Study of Two Dasatinib 100 mg Formulations in Healthy Colombians

  2016cites this paper
• Characterization of forced degradation products of pazopanib hydrochloride by UHPLC-Q-TOF/MS and in silico toxicity prediction.

  2015cites this paper
• Electrochemistry of Nonconjugated Proteins and Glycoproteins. Toward Sensors for Biomedicine and Glycomics

  2015cites this paper
• Development and Validation of an HPLC-UV Method for Pazopanib Quantification in Human Plasma and Application to Patients With Cancer in Routine Clinical Practice

  2015influential citation
• A simple method for the determination of Bosutinib in rat plasma by UPLC-MS/MS.

  2015cites this paper
• Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors--review of assay methodologies and perspectives.

  2015cites this paper
• Determination of bosutinib in mice plasma and tissue by UPLC-MS/MS and its application to the pharmacokinetic and tissue distribution study

  2015cites this paper
• Incorporation of inorganic components into organic matrices on the basis of polymer swelling in inorganic precursors as a way of composite materials synthesis without modifier application

  2015cites this paper
• Micellar enhanced synchronous spectrofluorimetric method for determination of dasatinib in tablets, human plasma and urine: application to in vitro drug release and content uniformity test

  2015cites this paper
• Separation, Identification, and Characterization of Degradation Products of Erlotinib Hydrochloride Under ICH-Recommended Stress Conditions by LC, LC-MS/TOF

  2015cites this paper
• Development and Validation of an HPLC-UV Method for Sorafenib Quantification in Human Plasma and Application to Patients With Cancer in Routine Clinical Practice

  2014cites this paper
• Simultaneous determination of erlotinib and metabolites in human urine using capillary electrophoresis

  2014cites this paper
• CZE Separation of New Drugs for Treatment of Leukemia

  2014cites this paper
• High-performance liquid chromatographic method for the determination of dasatinib in rabbit plasma using fluorescence detection and its application to a pharmacokinetic study.

  2013cites this paper
• Graphene based electrochemical biosensor for label-free measurement of the activity and inhibition of protein tyrosine kinase.

  2013cites this paper
• Protein kinase inhibitor analysis with the core–shell separation technique

  2012cites this paper
• Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma.

  2012cites this paper